Do Traders Think Cerus Corporation (CERS) Can Keep Climbing Thursday?

Cerus Corporation (CERS) stock has gained 18.46% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.

Cerus Corporation has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on CERS!

See Full CERS Report

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With CERS Stock Today?

Cerus Corporation (CERS) stock is trading at $1.54 as of 1:08 PM on Thursday, Nov 2, a gain of $0.16, or 11.59% from the previous closing price of $1.38. The stock has traded between $1.39 and $1.59 so far today. Volume today is less active than usual. So far 700,987 shares have traded compared to average volume of 996,690 shares. To screen for more stocks like Cerus Corporation click here.

More About Cerus Corporation

Cerus Corp is a biomedical products company focused in the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same. Click Here to get the full Stock Report for Cerus Corporation stock.